本文言語 | English |
---|---|
ページ(範囲) | 541-542 |
ページ数 | 2 |
ジャーナル | Australian and New Zealand Journal of Psychiatry |
巻 | 54 |
号 | 5 |
DOI | |
出版ステータス | Published - 2020 5月 1 |
ASJC Scopus subject areas
- 精神医学および精神衛生
UN SDG
この成果は、次の持続可能な開発目標に貢献しています
文献へのアクセス
他のファイルとリンク
引用スタイル
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Australian and New Zealand Journal of Psychiatry, Vol. 54, No. 5, 01.05.2020, p. 541-542.
研究成果: Letter › 査読
}
TY - JOUR
T1 - Clozapine-related gastrointestinal perforation
T2 - four case reports
AU - Nakajima, Nozomi
AU - Misawa, Fuminari
AU - Fujii, Yasuo
AU - Takeuchi, Hiroyoshi
N1 - Funding Information: Nakajima Nozomi 1 Misawa Fuminari 1 Fujii Yasuo 1 https://orcid.org/0000-0002-8844-4786 Takeuchi Hiroyoshi 2 1 Yamanashi Prefectural Kita Hospital, Yamanashi, Japan 2 Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan Hiroyoshi Takeuchi, Department of Neuropsychiatry, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. Email: hirotak@dk9.so-net.ne.jp 11 2019 0004867419887231 © The Royal Australian and New Zealand College of Psychiatrists 2019 2019 The Royal Australian and New Zealand College of Psychiatrists canadian institutes of health research https://doi.org/10.13039/501100000024 centre for addiction and mental health https://doi.org/10.13039/100010523 japanese society of clinical neuropsychopharmacology https://doi.org/10.13039/100009048 astellas foundation for research on metabolic disorders https://doi.org/10.13039/501100007263 dainippon sumitomo pharma https://doi.org/10.13039/501100002975 edited-state corrected-proof Declaration of Conflicting Interests Dr N.N. has no competing interests to disclose. Dr F.M. has received speaker’s honoraria from Eli Lilly, Janssen, Novartis Pharma, Otsuka, Pfizer and Sumitomo Dainippon Pharma. Dr Y.F. has received speaker’s honoraria from Janssen and Otsuka. Dr H.T. has received fellowship grants from the Canadian Institutes of Health Research (CIHR), Centre for Addiction and Mental Health (CAMH) Foundation, the Japanese Society of Clinical Neuropsychopharmacology and Astellas Foundation for Research on Metabolic Disorders; speaker’s honoraria from Meiji Seika Pharma, Mochida, Otsuka, Sumitomo Dainippon Pharma and Yoshitomiyakuhin; and manuscript fees from Sumitomo Dainippon Pharma. Funding The author(s) received no financial support for the research, authorship and/or publication of this article. ORCID iD Hiroyoshi Takeuchi https://orcid.org/0000-0002-8844-4786
PY - 2020/5/1
Y1 - 2020/5/1
UR - http://www.scopus.com/inward/record.url?scp=85075146197&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85075146197&partnerID=8YFLogxK
U2 - 10.1177/0004867419887231
DO - 10.1177/0004867419887231
M3 - Letter
C2 - 31718230
AN - SCOPUS:85075146197
SN - 0004-8674
VL - 54
SP - 541
EP - 542
JO - Australian and New Zealand Journal of Psychiatry
JF - Australian and New Zealand Journal of Psychiatry
IS - 5
ER -